CONMED
CNMD
281 hedge funds and large institutions have $4.69B invested in CONMED in 2022 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 95 increasing their positions, 105 reducing their positions, and 14 closing their positions.
129% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 14
6% more funds holding
Funds holding: 265 → 281 (+16)
3% more capital invested
Capital invested by funds: $4.55B → $4.69B (+$134M)
0.24% less ownership
Funds ownership: 109.95% → 109.71% (-0.24%)
10% less repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 105
89% less call options, than puts
Call options by funds: $2.32M | Put options by funds: $21.9M
Top Buyers
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$35.2M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$28.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$20.6M |
| 4 |
Jennison Associates
New York
|
+$18.6M |
| 5 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
+$11.2M |
Top Sellers
CNMD Hedge Fund Activity: Q1 2022 in Review
281 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in CONMED (CNMD) for Q1 2022, worth a combined $4.69B — up 3% from $4.55B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new CNMD positions and 14 closed out — a net gain of 18 holders — while 95 added to existing stakes and 105 trimmed.
The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $35.2M. The largest seller was Invesco, cutting an estimated $40.2M.
- 281 institutional investors held CONMED (CNMD) as of Q1 2022, up from 265 in Q4 2021.
- Funds reported $4.69B of CONMED stock for Q1 2022, up 3% quarter-over-quarter.
- 32 funds opened new CONMED positions in Q1 2022 and 14 closed out, a net change of +18 holders.
- The largest CONMED buyer in Q1 2022 was Lord, Abbett & Co, an estimated $35.2M added.
- The largest CONMED seller in Q1 2022 was Invesco, an estimated $40.2M sold.
Based on aggregated 13F filings for Q1 2022.